Pharmaceuticals

 

 

 

      
 

• Industry-leading growth – Novartis one of the fastestgrowing companies in the pharmaceutical industry, gaining market segment share and climbing one notch, to fifth place in global rankings
• Key growth drivers – The Cardiovascular and Oncology franchises; Diovan becomes the world’s leading angiotensin receptor blocker (ARB)
• Strong patent position – Low exposure to generic competition during the next five years

 

  

• Sustained research and development productivity – Seven major approvals during 2003; 11 new medicines launched in the US since 2000
• Deep pipeline again rated as one of the industry’s strongest by financial analysts – 79 projects in clinical development or registration
• Research and Development spending reaches 19% of sales – Reflecting high-level investment in the new US research center at Cambridge, Massachusetts and the addition of new development projects

 

  
 
 
 
 
  The Novartis Pharmaceuticals Division is a world leader in the discovery, development, manufacture and marketing of prescription medicines. Our goal is to provide a broad portfolio of innovative, effective and safe products   and services to patients through healthcare professionals around the world. This goal is supported by a dedicated organization operating in more than 140 countries.  
9